Welcome to our dedicated page for Ingevity SEC filings (Ticker: NGVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ingevity Corporation (NYSE: NGVT) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered context to help interpret them. Ingevity is a specialty materials and chemical manufacturer organized into three segments—Performance Materials, Advanced Polymer Technologies and Performance Chemicals—and its filings document how these businesses are managed, restructured and financed over time.
Investors can use Ingevity’s Form 10-K annual reports and Form 10-Q quarterly reports to review segment information, including sales and EBITDA for Performance Materials (activated carbon), Advanced Polymer Technologies (caprolactone polymers) and Performance Chemicals (specialty chemicals and pavement or road technologies). These reports also describe the applications for Ingevity’s products, such as adhesives, agrochemicals, asphalt paving, certified biodegradable bioplastics, coatings, elastomers, pavement markings, lubricants, oil drilling and automotive components.
Ingevity’s Form 8-K current reports are particularly important for tracking material events that affect NGVT stock. Recent 8-K filings detail the asset purchase agreement and subsequent amendment with Mainstream Pine Products, LLC for the sale of the North Charleston crude tall oil refinery and the majority of the Industrial Specialties product line, the classification of those operations as discontinued, and the completion of the transaction. Other 8-Ks describe leadership transitions in finance and business segments, the completion of a portfolio review and the decision to explore strategic alternatives for the Advanced Polymer Technologies segment and the Performance Chemicals Road Markings business, as well as preliminary earnings announcements.
On this page, AI-generated summaries highlight the key points of each filing, helping users quickly understand what a lengthy 8-K, 10-Q or 10-K means for Ingevity’s portfolio, margins, cash flow and capital allocation. Filings related to stock repurchases, strategic divestitures and executive changes are surfaced so that investors can monitor how the company is reshaping its specialty chemicals and materials portfolio. Users can also review exhibits referenced in 8-Ks, such as asset purchase agreements and recast financial information, to gain deeper insight into the structure and impact of major transactions.
Ingevity Corporation (NGVT) Form 4 filing: Director Francis David Segal reported the acquisition of 507 common shares on 07/01/2025 at an implied price of $44.40 per share. The shares were received through the vesting of deferred stock units (DSUs) elected in lieu of quarterly director fees under the company’s Non-Employee Director Deferred Compensation Plan and 2025 Omnibus Incentive Plan. Following the transaction, Segal’s direct beneficial ownership increased to 5,241 shares. No derivative securities were involved, and the transaction was coded “A” (acquisition) rather than an open-market purchase or sale. Because DSUs settle only after board service ends, the filing signals continued equity alignment but does not represent immediate cash investment.
Ingevity Corporation (NYSE: NGVT) filed a Form 8-K dated 1 July 2025 announcing the departure of S. Edward Woodcock, Executive Vice President and President of the Performance Materials segment (Item 5.02). The separation is effective the same day and a search for his successor has begun.
The company and Mr. Woodcock executed a Letter Agreement that mirrors provisions in his 2017 Severance and Change of Control Agreement. Key cash benefits include:
- A lump-sum payment within 30 days for accrued salary, prorated 2025 annual incentive, and unused vacation.
- Severance equal to one year of current base salary plus 2025 target bonus, payable monthly over 12 months.
- An additional $500,000 lump-sum tied to an October 2024 incentive award.
All consideration is conditioned on customary release of claims and ongoing covenant compliance (confidentiality, non-disparagement, non-competition, non-solicitation). The full Letter Agreement will be filed with the company’s Q2-25 10-Q.
Under Item 7.01, Ingevity furnished (but did not file) a press release (Exhibit 99.1) announcing the leadership change. No financial statements or earnings data were included.